Phathom Pharmaceuticals Financials - Benzinga

Phathom Pharmaceuticals Inc

PHATNASDAQ

Trade with Public

Trade with Public

$9.50

0.454.97%

At close: Sep 4, 5:00 PM EST

$9.41

-0.09-0.95%

After Hours: Sep 4, 7:31 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Phathom Pharmaceuticals Financials

Phathom Pharmaceuticals (PHAT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Phathom Pharmaceuticals Q2 Adj. EPS $0.00 Beats $(0.25) Estimate, Sales $74.300M Beat $72.789M Estimate

Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.25) by 100 percent. This is a 100 percent increase over losses of $(0.79) per share

Benzinga Newsdesk

PRO
Phathom Pharmaceuticals Lowers FY2026 Sales Guidance from $320.000M-$345.000M to $310.000M-$325.000M vs $332.196M Est

Phathom Pharmaceuticals (NASDAQ:PHAT) lowers FY2026 sales outlook from $320.000 million-$345.000 million to $310.000 million-$325.000 million vs $332.196 million estimate.

Benzinga Newsdesk

PRO
Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M Estimate

Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly sales of $74.300 million which beat the analyst consensus estimate of $72.789 million by 2.08 percent. This is a 88.09 percent increase over sales of $39.503

Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

PRO
Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $320.000M-$345.000M vs $331.417M Est

Phathom Pharmaceuticals (NASDAQ:PHAT) affirms FY2026 sales outlook from $320.000 million-$345.000 million to $320.000 million-$345.000 million vs $331.417 million estimate.

Benzinga Newsdesk

PRO
Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate

Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.32) by 43.75 percent. This is a 83.18 percent increase over losses of $(1.07) per

Benzinga Newsdesk